779 related articles for article (PubMed ID: 10989702)
21. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
[TBL] [Abstract][Full Text] [Related]
22. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
23. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
Chowdhary R; Dhole TN
J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
[TBL] [Abstract][Full Text] [Related]
24. Circulating vaccine-derived polioviruses: current state of knowledge.
Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
[TBL] [Abstract][Full Text] [Related]
25. Characterization of mutations in the VP(1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran.
Rahimi P; Tabatabaie H; Gouya MM; Zahraie M; Mahmudi M; Ziaie A; Rad KS; Shahmahmudi Sh; Musavi T; Azad TM; Nategh R
J Clin Virol; 2007 Aug; 39(4):304-7. PubMed ID: 17590391
[TBL] [Abstract][Full Text] [Related]
26. Update on vaccine-derived polioviruses--worldwide, January 2006-August 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(38):996-1001. PubMed ID: 17898693
[TBL] [Abstract][Full Text] [Related]
27. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
28. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.
Fine PE; Carneiro IA
Am J Epidemiol; 1999 Nov; 150(10):1001-21. PubMed ID: 10568615
[TBL] [Abstract][Full Text] [Related]
29. Possible global strategies for stopping polio vaccination and how they could be harmonized.
Cochi SL; Sutter RW; Aylward RB
Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
[TBL] [Abstract][Full Text] [Related]
30. [Genetic evolution of poliovirus: success and difficulties in the eradication of paralytic poliomyelitis].
Blondel B; Autret A; Brisac C; Pelletier I; Martin-Latil S; Jegouic S; Bessaud M; Joffret ML; Balanant J; Colbère-Garapin F; Delpeyroux F
Med Trop (Mars); 2008 Apr; 68(2):189-202. PubMed ID: 18630055
[TBL] [Abstract][Full Text] [Related]
31. [Vaccination strategies for the global eradication of poliomyelitis].
Bompart F
Bull Soc Pathol Exot; 2004 Nov; 97(4):288-92. PubMed ID: 17304754
[TBL] [Abstract][Full Text] [Related]
32. Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model.
Thorley B; Kelly H; Nishimura Y; Yoon YK; Brussen KA; Roberts J; Shimizu H
J Clin Virol; 2009 Apr; 44(4):268-71. PubMed ID: 19269246
[TBL] [Abstract][Full Text] [Related]
33. World wide experience with inactivated poliovirus vaccine.
Bonnet MC; Dutta A
Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
[TBL] [Abstract][Full Text] [Related]
34. [Worldwide eradication of poliomyelitis].
Rasch G; Schreier E; Kiehl W; Kurth R
Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
[TBL] [Abstract][Full Text] [Related]
35. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
36. The pathogenesis of poliomyelitis: what we don't know.
Nathanson N
Adv Virus Res; 2008; 71():1-50. PubMed ID: 18585526
[TBL] [Abstract][Full Text] [Related]
37. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis.
Khetsuriani N; Prevots DR; Quick L; Elder ME; Pallansch M; Kew O; Sutter RW
J Infect Dis; 2003 Dec; 188(12):1845-52. PubMed ID: 14673763
[TBL] [Abstract][Full Text] [Related]
38. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
[TBL] [Abstract][Full Text] [Related]
39. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
Aylward RB; Cochi SL
Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
[TBL] [Abstract][Full Text] [Related]
40. Policy. OPV cessation--the final step to a "polio-free" world.
Aylward RB; Sutter RW; Heymann DL
Science; 2005 Oct; 310(5748):625-6. PubMed ID: 16254173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
